The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy

Cancer Journal from Scientific American

Volumn 3, Issue SUPPL. 1, 1997, Pages

  Lotze, Michael T ^a   Hellerstedt, Beth ^a   Stolinski, Lori ^a   Tueting, Thomas ^a   Wilson, Cara ^a   Kinzler, Donna ^a   Vu, Huan ^a   Rubin, Joshua T ^a   Storkus, Walter ^a   Tahara, Hideaki ^a   Elder, Elaine ^a   Whiteside, Theresa ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Dendritic cells; Interleukin 12; Interleukin 2

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2;

ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELL TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; FIBROBLAST; HUMAN; HUMAN EXPERIMENT; IMMUNOMODULATION; KIDNEY CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0031425109     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Lotze MT, Chang AK, Seipp CA et al. High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity, and histologic findings. JAMA 1986;256:3117-3124.
2. Rosenberg SA, Mule JJ, Spiess PJ et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant IL-2. J Exp Med 1985;161:1169-1188.
3. Rosenberg SA, Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 1987;316:889-897.
4. Royal RE, Steinberg SM, Krouse RS et al. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am 1996;2:91-98.
5. Lotze MT, Line BR, Mathisen DJ et al. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. J Immunol 1980;125:1487-1493.
6. Lotze MT, Grimm EA, Mazumder A et al. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 1981;41:4420-4425.
7. Mule JJ, Shu S, Schwarz SL et al. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin 2. Science 1984;225:1487-1489.
8. Mule JJ, Shu S, Rosenberg SA. The antitumor efficacy of lymphokine activated killer cells and recombinant interleukin 2 in vivo. J Immunol 1985;135:646-652.
9. Lafreniere R, Rosenberg SA. Successful immunotherapy of murine experimental hepatic metastases with lymphokine activated killer cells and recombinant experimental interleukin 2. Cancer Res 1985;45:3735-3741.
10. Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-1492.
11. Lotze MT. Getting to the source: dendritic cells as therapeutic reagents for the treatment of cancer patients [editorial]. Ann Surg 1997;226:1-5.
12. Wilson CC, Tueting T, Ma DI et al. Activation of dendritic cells by surrogate T cell interactions leads to enhanced costimulation, secretion of TH1-associated cytokines, and CTL inductive capacity. In: Ricciardi-Castagnoli P, ed. Proceedings of the IV International Symposium on Dendritic Cells in Fundamental and Clinical Immunology, Vol 3. New York; Plenum Press, 1996.
13. Turing T, Storkus WJ, Lotze MT. Gene-based strategies for the immunotherapy of cancer. Mol Medicine 1997;75:478-491.
14. Falo LD, Lotze MT. Cancer vaccines. In: Rose NR, de Macario EC, Folds JD et al, eds. Manual of Clinical Laboratory Immunology, 5th ed. Washington, DC; ASM Press:1041.
15. Vakkila J, Hurme M. Both dendritic cells and monocytes induce autologous and allogeneic T cells receptive to interleukin 2. Scand J Immunol 1990;31:75-83.
16. Van Snick J. IL-6: an overview. Ann Rev Immunol 1990;8:253-278.
17. Noma T, Mizuta T, Rosen A et al. Enhancement of the interleukin 2 receptor expression on T cells by multiple B-lymphotropic lymphokines. Immunol Lett 1987;15:249-253.
18. Houssiau FA, Coulie PG, Van Snick J et al. Distinct roles of IL-1 and IL-6 in human T cell activation. J Immunol 1989;143:2520-2524.
19. Okada M, Kitahara M, Kishimoto S et al. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 1988;141:1543-1549.
20. Takai Y, Wong GG, Clarck SC et al. B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes. J Immunol 1988;140:508-512.
21. Uyttenhove C, Coulie PG, Van Snick J. T cell growth and differentiation induced by interleukin-HPI/IL-6, the murine hybridoma/plasmacytoma growth factor. J Exp Med 1988;167:1417-1427.
22. Stouthard JM, Goey H, de Vries EG et al. Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial. Br J Cancer 1996;73:789-793.
23. Blay JY, Negrier S, Combaret V et al. Serum level of interleukin-6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992;52:3317-3322.
24. Kamemoto H. Significance of plasma interleukin-6 in the diagnosis of renal cell carcinoma. Hinyokika Kiyo 1993;39:301-306.
25. Stadler WM, Richards JM, Vogelzang NJ. Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicator. J Nad Cancer Inst 1992;84:1835-1836.
26. Schwarz MA, Hamilton LD, Tardelli L et al. Stimulation of cytolytic activity by interleukin-10. J Immunother 1994;16:95-104.
27. Cohen SB. IL-10 and IL-3 synergize to cause proliferation of human T cells. Immunology 1995;85:351-356.
28. Kundu N, Beaty TL, Jackson MJ et al. Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst 1996;88:536-541.
29. Berman RM, Suzuki T, Tahara H et al. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol 1996;157:231-238.
30. Kobayashi M, Fitz L, Ryan M et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989; 170:827-845.
31. Suzuki T. Tahara H, Robbins P et al. Viral interleukin-10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors. J Exp Med 1995;182:477-486.
32. Wong HL, Wilson DE, Jenson JC et al. Characterization of a factor(s) which synergizes with recombinant interleukin 2 in promoting allogeneic human cytolytic T-lymphocyte responses in vitro. Cell Immunol 1988;111:39-54.
33. Nastala CL, Edington HD, McKinney TG et al. Recombinant IL12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994;153:1697-1706.
34. Wiebke EA, Rosenberg SA, Lorze MT et al. Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens. J Clin Oncol 1988;6:1440-1449.
35. Roake D, Austyn J. Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin-1. J Exp Med 1995;181:2237-2247.
36. Zhang J, Wenthold RJ, Yu ZX et al. Characterization of the pulmonary lesions induced in rats by human recombinant interleukin-2. Toxicol Pathol 1995;23:653-666.
37. Kradin RL, Xia W, Pike M et al. Interleukin-2 promotes the motility of dendritic cells and their accumulation in lung and skin. Pathobiology 1996;64:180-186.
38. Elder EM, Stolinski LA, Whiteside TL et al. Interleukin 2 treatment causes acute loss of DC precursors and mature DC which rebound with the increase in lymphocytes. J Immunother; in press.
39. Savary C et al. Multidimensional flow cytometric analysis of dendritic cells in the peripheral blood of normal donors and cancer patients. Cancer Immunol Immunother; in press.
40. Celluzzi CM, Mayordomo JI, Storkus WJ et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-287.
41. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic celk pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity. Nature Medicine 1995; 1:1297-1302.
42. Türing T, Zorina T, Ma DI et al. Development of dendritic cell-based genetic vaccines for cancer. In: Ricciardi-Castagnoli P, ed. Proceedings of the IV International Symposium on Dendritic Cells in Fundamental and Clinical Immunology, Vol 3. New York; Plenum Press, 1996.
43. Türing T, DeLeo AB, Lotze MT et al. Bone marrow-derived dendritic cells genetically modified to express tumour-associated antigens induce antitumour immunity in vivo. Nature Medicine; submitted.
44. Zitvogel L, Mayordomo JI, Tjandrawan T et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell-associated cytokines. J Exp Med 1996;183:87-97.
45. Nestle FO, Gilliet M, Alijagic S et al. Vaccination of melanoma patients with peptide-pulsed dendritic cells. Melanoma Res 1997; 7:S14(047).
46. McKenna HJ, de Vries P, Brasel K et al. Effect of flt3 ligand on the ex vivo expansion of human CD34+ hematopoietic progenitor cell Blood 1995;86:3413-3420.
47. Rusten LS, Lyman SD, Veiby OP et al. The FLT3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro. Blood 1996;87:1317-1325.
48. Siena S, Di Nicola M, Bregni M et al. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hematol 1995;23:1463-1471.
49. Saraya K, Reid CD. Stem cell factor and the regulation of dendritic cell production from CD34+ progenitors in bone marrow and cord blood. BrJ Haematol 1996;93:258-264.
50. Shurin MR, Pandharipande PP, Zorina TD et al. FLT3-ligand-induced generation of functionally active dendritic cells in mice. Cell Immunol 1997;179:174-184.
51. Tahara H, Zitvogel L, Storkus WJ et al. Phase I clinical trial of interleukin-12 (IL-12) gene therapy using direct injection of tumors with genetically engineered fibroblasts. Proceedings of ASCO 1996;15:235.